Whether an immuno-oncology treatment option will arise in the oesophageal cancer space is garnering attention.

BeiGene Korea's immuno-oncology drug Tevimbra (tislelizumab) passed the Health Insurance Review and Assessment Service’s Cancer Disease Review Committee in August during its second attempt. Tevimbra is a PD-1 inhibiting immuno-oncology drug that has demonstrated clinical utility in second-line oesophageal squamous cell carcinoma and was approved in Korea in November last year.

Currently, there are seven immuno-oncology drugs licensed and marketed in Korea, including ▲Keytruda, ▲Opdivo, ▲Tecentriq, ▲Imfinai, ▲Bavencio, ▲Jemperli, and ▲Tevimbra, which owns a total of 64 in